Mobidiag, Bioportugal Collaborate
News Sep 27, 2016
Mobidiag Ltd has announced an agreement with Bioportugal Química Farmacêutica Lda for the distribution of the Amplidiag® product line. Under this agreement Bioportugal becomes the exclusive distributor of Amplidiag®, in vitro diagnostics for gastrointestinal infections, in Portugal.
“For the past months, we have been extending significantly our European distribution network. With a strong background in diagnostics, Bioportugal seemed to be the clear choice to distribute our IVD tests in Portugal. We are then very pleased to expand even more Amplidiag accessibility with the support of Bioportugal” said Tuomas Tenkanen, CEO at Mobidiag.
“Bioportugal is one of the leader companies in the molecular diagnostic in Portugal and we have been supplying several branches world recognized for the last 15 years. Modidiag portfolio of products is perfect to complete our existing list. It was a gap in our portfolio and with Mobidiag range of products we expect to cover a more extensive list of clients, increase business and have a profitable relationship for both parts” said Joaquim Teixeira, CEO at Bioportugal.
The distribution agreement is effective immediately and covers all Amplidiag® products (Amplidiag® H. pylori+ClariR, Amplidiag® Stool Parasites, Amplidiag® CarbaR+VRE, Amplidiag® C. difficile+027, Amplidiag® Bacterial GE, Amplidiag® Easy and upcoming Amplidiag® Viral GE).
Tweak to Technique Could Bolster Disease DetectionNews
A team of Stanford researchers has developed a technique that they hope could more precisely detect diseases or disorders such as cancer or a heart attack.READ MORE
Immune Cells That Keep Gut Fungi Under Control IdentifiedNews
Immune cells that process food and bacterial antigens in the intestines control the intestinal population of fungi, according to a new study from Weill Cornell Medicine scientists.READ MORE
New Biomarkers Predict Outcome of Cancer ImmunotherapyNews
Researchers at the University of Zurich have identified biomarkers in the blood that make it possible to predict whether cancer patients will respond positively to immunotherapy. Patients for whom therapy does not work can thus be treated using different methods at an earlier stage.READ MORE